We aimed to assess the effect of the addition of cediranib (an oral inhibitor of VEGF receptor 1, 2, and 3) to cisplatin and gemcitabine on progression-free survival.
READ FULL ARTICLE
From Thelancet
Survival Biliary Tract Cancer Treated with Cediranib, Cisplatin and Gemcitabine
the Cancer Therapy Advisor take:
Patients diagnosed with advanced biliary tract cancer who were administered cediranib had more grade 3 to 4 toxic effects compared to those who received a placebo, according to an article published online in the journal The Lancet Oncology.
Participants in this study included patients with histologically or cytologically confirmed advanced biliary tract cancer, an ECOG performance status of 0 to 1, and a life expectancy estimate of more than 3 months.
The patients were given cisplatin and gemcitabine chemotherapy (25 mg/m2 and 1,000 mg/m2, respectively) at baseline for up to eight cycles, and then they were either administered 20 mg oral cediranib or placebo once daily until disease progression.
Results showed 62 patients received oral cediranib and 62 patients were administered placebo (from April 2, 2011, to Sept. 28, 2012).
Patients’ median follow-up time was 12.2 months (IQR 7.3, 18.5). In the cediranib cohort, median progression-free survival was 8.0 months (95% CI: 6.5, 9.3), compared to 7.4 months (5.7, 8.5) in the placebo cohort (HR, 0.93; 80% CI: 0.74, 1.19; 95% CI: 0.65, 1.35; P=0.72).
Furthermore, patients who were administered cediranib experienced more grade 3 to 4 toxic adverse effects compared to those in the placebo cohort, including hypertension (23 [37%] vs. 13 [21%]; P=0.05), diarrhea (eight [13%] vs. two [3%]; P=0.05); decreased platelet count (10 [16%] vs. four [6%]; P=0.09), decreased white blood cell (15 [24%] vs. seven [11%]; P=0.06) and fatigue (16 [24%] vs. seven [11%]; P=0.04).
